상세 보기
Nanoparticle-Based Chimeric Antigen Receptor Therapy for Cancer Immunotherapy
- Shin, S.;
- Lee, P.;
- Han, J.;
- Kim, S.-N.;
- Lim, J.;
- ... Paik, Tae Jong;
- ... Min, Junhong;
- 외 3명
WEB OF SCIENCE
34SCOPUS
39초록
Adoptive cell therapy with chimeric antigen receptor (CAR)-engineered T cells (CAR-Ts) has emerged as an innovative immunotherapy for hematological cancer treatment. However, the limited effect on solid tumors, complex processes, and excessive manufacturing costs remain as limitations of CAR-T therapy. Nanotechnology provides an alternative to the conventional CAR-T therapy. Owing to their unique physicochemical properties, nanoparticles can not only serve as a delivery platform for drugs but also target specific cells. Nanoparticle-based CAR therapy can be applied not only to T cells but also to CAR-natural killer and CAR-macrophage, compensating for some of their limitations. This review focuses on the introduction of nanoparticle-based advanced CAR immune cell therapy and future perspectives on immune cell reprogramming. © 2023, Korean Tissue Engineering and Regenerative Medicine Society.
키워드
- 제목
- Nanoparticle-Based Chimeric Antigen Receptor Therapy for Cancer Immunotherapy
- 저자
- Shin, S.; Lee, P.; Han, J.; Kim, S.-N.; Lim, J.; Park, D.-H.; Paik, Tae Jong; Min, Junhong; Park, C.G.; Park, W.
- 발행일
- 2023-06
- 유형
- Review
- 권
- 20
- 호
- 3
- 페이지
- 371 ~ 387
- 언어
- ENG
- 출판사
- Korean Tissue Engineering and Regenerative Medicine Society
- 발행국가
- 대한민국
- 분량
- 17 페이지
- ISSN
- E 2212-5469
P 1738-2696